On February 6, 2024, Attralus, Inc. closed the transaction. The company received $55,999,932 in the final tranche led by new investor, Alpha Wave Global, LP. The transaction included participation from a new investor, Bristol-Myers Squibb Company and venBio LLC, Vivo Capital, LLC, Surveyor Capital Management, Logos Global Management, L.P. and Sarissa Capital Management LP.